nabu.science
MethodologyAboutContact

 

Reliability concern: This paper was retracted on 2024-02-21. See notice: 10.3389/fonc.2024.1383383.

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-A93C2D9A·Framework v5.0·Pipeline v0.4·Evaluated 01 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Radiology, Nuclear Medicine and Imaging·Basis: Full text·Type: Cross-sectional study

The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.

He et al.He, Wang, Zhou et al.·2023·Frontiers in oncology·10.3389/fonc.2023.1132186 ↗

In brief

A small single-centre TNBC imaging study whose material internal inconsistencies in reported diagnostic metrics undermine its modest incremental contribution.

ReliabilityConcerns4 of 4 checks completeRead the 3 entries ↓
Abstract

BACKGROUND: Breast cancer (BC) is a common malignant tumor in female. In recent years, with the change of fertility pattern and lifestyle, the incidence of breast cancer is increasing year by year, seriously endangering the health and life of women. MRI is suitable for follow-up evaluation of the course of neoadjuvant chemotherapy in LABC, but there are few related studies and reports. Based on the above background, it is necessary to further evaluate the value of functional magnetic resonance imaging in neoadjuvant chemotherapy in patients with triple negative breast cancer, so as to lay a theoretical foundation for the popularization and application of this detection method. Based on this, this study was to explore the value, diagnostic efficacy and clinical importance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.

METHODS: A total of 62 patients with triple-negative breast cancer who received neoadjuvant chemotherapy in our hospital from September 2017 to September 2022 were selected. To compare the differences of functional magnetic resonance imaging (fMRI) between effective and ineffective patients with neoadjuvant chemotherapy, the related data were statistically analyzed.

RESULTS: There was no significant difference between the mode of tumor withdrawal and the pathological complete remission of tumor tissue (P>0.05). There was no significant difference in anti-Trop-2 antibody-drug conjugates (ADC) data before and after chemotherapy between over-expressed patients with human epidermal growth factor receptor-2 (HER-2) and non-over-expressed patients with HER-2 (P>0.05). The levels of ADC and Δ ADC in pathological complete remission patients after chemotherapy were significantly higher than those in non-pathological complete remission patients (P<0.05). Using the ΔADC value as the evaluation parameter, the pathological response of tumor tissue was classified as the "gold standard" to draw the ROC curve, the area under curve (AUC) was 0.673, the cut-off of ΔADC to evaluate the significant response of tumor tissue after chemotherapy was 1.418, the sensitivity of evaluating the efficacy was 71.9%, and the specificity was 55.0%.

CONCLUSION: Functional magnetic resonance imaging (fMRI) has diagnostic value for neoadjuvant chemotherapy in patients with triple negative breast cancer. According to the change of ADC value, the curative effect can be predicted early and the treatment strategy can be adjusted in time.

Strengths · Limitations

Strengths

#contribution

Clinically relevant question with defined population

The study targets a specific clinical need — non-invasive early prediction of NAC response in TNBC — with a clearly defined patient population and a pathological reference standard (Miller-Payne classification).

↳ Methods section (inclusion criteria, pathological evaluation)

#methodological rigour

Adequate MRI technical specification

The MRI acquisition protocol is described with sufficient technical detail, including scanner model (GE Signa Excite HD 3.0T), coil type, b-value (1000 s/mm²), and sequence parameters (TR, TE, slice thickness), enabling basic methodological assessment.

↳ Methods section (Instrument and scanning method)

#positioning

Honest limitation acknowledgment and prior work citation

The Discussion cites directly relevant prior studies (Ehsani An, Allard-Coutu A, Siow Z.R) and explicitly acknowledges the need for multicenter, larger-sample validation before clinical application.

↳ Discussion section (final paragraphs, references 41-44)

Limitations

#methodological rigour

Material inconsistency in primary diagnostic metrics

The paper's headline ROC results differ between sections: AUC 0.673 (Results) vs. 0.654 (Discussion), sensitivity 71.9% vs. 61.5%, specificity 55.0% vs. 75.0%, and cut-off 1.418 vs. 1.272×10⁻³ mm²/s. These are not rounding differences and prevent determination of the actual findings.

↳ Abstract/Results section vs. Discussion section

#methodological rigour

Erroneous ethics statement and conduct gaps

The Ethics Statement refers to an 'animal study' approval for a human patient study, the approving body name differs between Methods and Ethics sections, no conflict of interest statement is provided, and the data availability claim is unverifiable.

↳ Ethics Statement section, Methods section, end matter

#methodological rigour

No confounder control or reliability reporting

The primary ADC comparison between responders and non-responders is unadjusted for tumor stage, chemotherapy regimen, or baseline characteristics. Despite describing a double-blind reading protocol, inter-reader reliability (ICC or kappa) is not reported.

↳ Methods section (Statistical Analysis), Results section

Does this match your read? Add your assessment ↓

Withdrawn — shown for reference only

Nabu Commentary

This small single-centre retrospective study examines whether ADC changes from diffusion-weighted MRI can predict pathological complete response to neoadjuvant chemotherapy in 62 TNBC patients. The research question is clinically relevant, and the general study framework is appropriate. However, the paper's primary finding — the ROC analysis of ΔADC — is reported with two different sets of values between the Results and Discussion sections (AUC 0.673 vs. 0.654; sensitivity 71.9% vs. 61.5%; specificity 55.0% vs. 75.0%), a material inconsistency that cannot be resolved from the text and which undermines confidence in the core contribution. Additional methodological gaps — no confounder adjustment, unreported inter-reader reliability, no confidence intervals, and an erroneous 'animal study' ethics statement — further reduce the evidential strength. The modest discriminatory performance (AUC below 0.7 on either reported value) is overclaimed as having 'diagnostic value' warranting clinical application.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.2±0.2

Contribution
2.3

The study addresses a clinically relevant question about ADC-based prediction of NAC response in TNBC, but it adds incrementally to a well-established literature without clearly articulating its novel contribution. The modest AUC (~0.65–0.67), small sample (N=62), and overclaiming of 'diagnostic value' relative to the weak discriminatory performance place this in the range of a contribution substantially limited by execution.

Abstract (AUC claim), Discussion (acknowledgment of prior studies by Ehsani An, Allard-CoutuA, Siow Z.R; acknowledgment of need for multicenter study)

multicenter and large sample study is needed for the application of ADC in clinical diagnosis

Methodological Rigour
2.0

The retrospective observational design with ROC analysis is an appropriate framework, but execution is weakened by absent confounder adjustment, unreported inter-reader reliability despite a double-blind protocol, no confidence intervals for diagnostic metrics, and a HER-2 subgroup analysis that is a category error for TNBC. The Red reliability flag caps the editorial Methodological Rigour score at 2.0 from a merit-based assessment of 2.4, driven by the material numerical discrepancy in the paper's primary ROC outcome between Results and Discussion sections.

Methods (double-blind analysis, ROI methodology), Results vs Discussion (AUC 0.673 vs 0.654, sensitivity 71.9% vs 61.5%, specificity 55.0% vs 75.0%), Table 3 (HER-2 analysis)
Reporting
2.6

The paper follows a conventional IMRaD structure that is broadly navigable, but clarity is substantially impaired by terminological imprecision — 'fMRI' in the title and abstract for what is DWI/ADC, and the ADC abbreviation used for both Apparent Diffusion Coefficient and antibody-drug conjugates. The numerical discrepancy between Results and Discussion means a reader cannot determine the actual diagnostic performance metrics.

Title, Abstract (fMRI terminology, ADC abbreviation conflict), Results section vs Discussion (inconsistent ROC values)

anti-Trop-2 antibody-drug conjugates (ADC)

Positioning
2.4

The paper cites several relevant prior studies on ADC and NAC response in breast cancer (Ehsani An, Allard-CoutuA, Siow Z.R) and acknowledges limitations including small sample size. However, engagement is superficial — no comparison of the study's AUC against prior work, no discussion of consistency with existing evidence, and no STROBE or equivalent reporting standard compliance.

Discussion (citations to prior studies), Discussion (limitations paragraph)

Reliability

Concerns4 of 4 checks


Internal CoherenceConcern

The paper's primary diagnostic performance metrics differ substantially between the Abstract/Results and the Discussion, representing a material inconsistency in the core findings that cannot be resolved from the text.

Research ConductConcern

The Ethics Statement contains a likely template error referring to an 'animal study' in what is clearly a human patient study, and the institutional naming is inconsistent between the Methods and the Ethics Statement. The data availability claim is unverifiable.

Flags: 2 declared / 5 total

Reference IntegrityClean

All 35 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordConcern

This paper was retracted on 2024-02-21. See notice: 10.3389/fonc.2024.1383383.

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Cancer and neoplasms · Breast cancer
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsFWCI 0.2
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The ΔADC threshold was shown working once against pathological gold standard in a small single-hospital cohort of 62 patients, with no independent or multicenter confirmation.

From the paper
“According to the changes of ADC value, the curative effect can be predicted early and the treatment strategy can be adjusted in time.”

The conclusion names a real clinical use (early prediction of chemotherapy efficacy to adjust treatment) but does not specify who would act on the findings or in what decision setting.

Pathway

Breast oncologists and radiologists could use ΔADC measurements during neoadjuvant chemotherapy to predict pathological response early and adjust or escalate treatment before surgery.

Barrier

The modest diagnostic accuracy (AUC 0.673, specificity 55%) and small single-center sample mean multicenter large-sample validation is needed before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. How Does Diagnostic Accuracy Evolve with Increased Breast MRI Experience?

    Wu, Alikhassi, Curpen · 2023 · Clinical medicine

    Primary claim

    Diagnostic accuracy improved exponentially with increased MRI experience (definition B, OR of 1.27 and 1.61 for 5 and 10 years, respectively, p = 0.03 for both).

    Tentative
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. General cognitive function and the brain's structural connectome

    Buchanan, Moodie, Batziou, et al. · 2026 · Basic medicine

    Primary claim

    g is supported by a widely distributed white matter network whose macroscopic wiring capacity, microstructural organisation, and age sensitivity contribute in distinct ways.

    Tentative
    Evidence Score
    3.6±0.2
    Reliability
    Caveats
  3. The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network

    Markiewicz, Thompson, Wardlaw, et al. · 2026 · Clinical medicine

    Primary claim

    CL values across 74 scans showed excellent test-retest agreement (ICC = 0.968), improving to 0.987 after exclusion of one attenuation correction related outlier.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →